Compounds > edotreotide
Page last updated: 2024-09-04

edotreotide and Neuroendocrine Tumors

edotreotide has been researched along with Neuroendocrine Tumors in 87 studies

Research

Studies (87)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (4.60)18.2507
2000's25 (28.74)29.6817
2010's39 (44.83)24.3611
2020's19 (21.84)2.80

Authors

AuthorsStudies
Boursier, C; Chevalier, E; Claudin, M; Filippetti, L; Huttin, O; Imbert, L; Marie, PY; Roch, V1
Abderrahim, N; Adriani, W; Ahmed, F; Algarra, M; Amor, HB; Andreasi, V; Bailey, RL; Bettinardi, V; Bezzi, C; Bithe, SA; Boumnijel, I; Burr, SE; Cadmus, P; Calcaprina, B; Canevari, C; Catalfamo, B; Chen, J; Chen, X; Chen, Y; Clements, WH; Cornick, J; Cotton, SJ; De Cobelli, F; Djellabi, R; Falconi, M; Ghezzo, S; Gianolli, L; Guarnaccia, A; Guo, X; Hart, JD; Hasan, MM; Head-Gordon, M; Iwasaki, Y; Kalua, K; Kong, X; Laviola, G; Li, L; Li, M; Liu, M; Mao, Y; Mapelli, P; Meleke, H; Messina, A; Miller, WH; Muffatti, F; Neher, B; Palumbo, D; Partelli, S; Peláez, D; Pepe, M; Picchio, M; Presotto, L; Ranville, J; Samanes Gajate, AM; Samikwa, L; Schiavo Lena, M; Scifo, P; Shu, H; Soto, J; Sun, W; Talbot, JJ; Tu, J; Vaquer, F; Weng, L; Wu, J; Xu, T; Zhang, D; Zhao, B; Zhao, K; Zhao, Y1
Buck, AK; Higuchi, T; Pomper, MG; Rowe, SP; Serfling, SE; Solnes, LB; Weich, A; Werner, RA1
Chiche, L; Debordeaux, F; Marichez, A; Passand, GT; Pinaquy, JB1
Champion, L; Cros, J; Hescot, S; Richard, C; Seban, RD1
Andreasi, V; Baldassi, F; Bezzi, C; Canevari, C; De Cobelli, F; Falconi, M; Ghezzo, S; Gianolli, L; Magnani, P; Mapelli, P; Muffatti, F; Partelli, S; Picchio, M; Schiavo Lena, M1
Fabritius, MP; Mansour, N; Rangan, K; Rübenthaler, J; Tiling, R1
Abughanmi, R; Al-Khatib, S; Al-Muqbel, K; Al-Smadi, R; Alardah, H1
Bélissant Benesty, O; Bertherat, J; Chanson, P; Michaud, L; Montravers, F; Nataf, V; Ohnona, J; Reznik, Y; Talbot, JN; Zhang-Yin, J1
Götz, TI; Kuwert, T; Lang, EW; Maier, A; Ritt, P; Schmidkonz, C1
Casar-Borota, O; Filipsson Nyström, H; Gjertsson, P; Heurling, K; Himmelman, J; Itsenko, O; Ragnarsson, O; Schöll, M; Tjörnstrand, A1
Baum, RP; Kulkarni, HR; Singh, A; Zhang, J1
Baum, RP; Kulkarni, HR; Zhang, J2
Cordes, M; Goetz, TI; Kuwert, T; Lang, EW; Maier, A; Prante, O; Ritt, P; Schmidkonz, C1
Casar-Borota, O; Filipsson Nyström, H; Gjertsson, P; Heurling, K; Ragnarsson, O; Schöll, M; Tjörnstrand, A1
Albano, D; Bertagna, F; Giubbini, R1
Chaudhry, MA; Lodge, MA; Solnes, LB; Wahl, RL1
Apostolidis, C; Apostolidis, L; Bicu, F; Bruchertseifer, F; Choyke, PL; Giesel, FL; Haberkorn, U; Kratochwil, C; Morgenstern, A; Rathke, H1
Bartolomei, M; Bertani, E; Crippa, S; Doglioni, C; Falconi, M; Fazio, N; Grana, CM; Muffatti, F; Partelli, S; Perali, C; Schiavo Lena, M; Zamboni, G1
Jeremic, MZ; Krstic, DZ; Matovic, MD; Nikezic, DR; Pantovic, SB1
Balogova, S; Huchet, V; Kerrou, K; Michaud, L; Montravers, F; Nataf, V; Talbot, JN1
Aschoff, P; Brendle, C; Claussen, CD; Lichy, MP; Müller, M; Pfannenberg, C; Schraml, C; Schwenzer, NF; Sperling, O; Werner, MK1
Banerjee, SR; Pomper, MG1
Bergsma, H; de Herder, WW; Kam, BL; Krenning, EP; Kwekkeboom, DJ; Peeters, RP; Teunissen, JJ; van Vliet, EI1
Cacciari, G; Campana, D; Capurso, G; Delle Fave, G; Falconi, M; Nori, F; Panzuto, F; Partelli, S; Tamburrino, D; Tomassetti, P1
Colandrea, M; Fracassi, SL; Gilardi, L; Paganelli, G; Sansovini, M1
Habibollahi, P; Heidari, P; Kulke, M; Mahmood, U; Wehrenberg-Klee, E; Yokell, D1
Baete, K; Bogaerts, K; Clement, PM; Deroose, CM; Haustermans, K; Koole, M; Mortelmans, L; Mottaghy, FM; Terwinghe, C; Van Binnebeek, S; Van Cutsem, E; Vanbilloen, B; Verbruggen, A; Verslype, C1
Cappellani, A; Cardì, F; Cavallaro, A; Cavallaro, M; Di Carlo, I; Di Mattia, P; Di Vita, M; Lo Menzo, E; Piccolo, G; Zanghì, A1
Apostolidis, C; Boll, R; Bruchertseifer, F; Giesel, FL; Haberkorn, U; Kratochwil, C; Mier, W; Morgenstern, A; Murphy, K1
Ishimori, T; Nakamoto, Y; Saji, H; Sano, K; Temma, T; Togashi, K; Ueda, M2
Baete, K; Bogaerts, K; Clement, PM; Deroose, CM; Haustermans, K; Koole, M; Mortelmans, L; Mottaghy, FM; Nackaerts, K; Terwinghe, C; Van Binnebeek, S; Van Cutsem, E; Vanbilloen, B; Verbruggen, A; Verslype, C1
Baio, SM; Bodei, L; Colandrea, M; Fazio, N; Galetta, D; Gilardi, L; Grana, CM; Mariniello, A; Paganelli, G; Papi, S; Tinelli, C; Valmadre, G1
Bartenstein, P; Baum, RP; Bengel, FM; Biersack, HJ; Dunkelmann, S; Ezziddin, S; Gratz, KF; Haug, A; Hörsch, D; Krause, BJ; Miederer, M; Pöpperl, G; Schreckenberger, M1
Alke, A; Essler, M; Henriksen, G; Miederer, M; Mossbrugger, I; Quintanilla-Martinez, L; Senekowitsch-Schmidtke, R1
Arveschoug, AK; Hjorthaug, K; Højgaard, L; Mortensen, J; Oturai, PS; Rehling, M1
Asti, M; Azzolini, F; Camellini, L; Carlinfante, G; Frasoldati, A; Fraternali, A; Gallo, C; Giunta, FP; Grassi, E; Iori, V; Nicoli, F; Salvo, D; Sassatelli, R; Versari, A1
Bares, R; Dudziak, K; Gallwitz, B; Häring, HU; Horger, M; Müssig, K; Oksüz, MO; Petersenn, S; Pfannenberg, C; Schulz, S; Ueberberg, B; Wehrmann, M1
Bodei, L; Paganelli, G; Pepe, G1
Freesmeyer, M; Knösel, T; Scholz, T; Schulz, S; Settmacher, U; Uberrueck, T; Wurst, Ch1
Denecke, T; Jann, H; Mehl, S; Ozcelik, C; Pape, U; Pavel, M; Wertenbruch, T; Wiedenmann, B1
Bockisch, A; Broelsch, CE; Frilling, A; Kuehl, H; Li, J; Malago, M; Radtke, A; Sotiropoulos, GC1
Hartmann, H; Luboldt, HJ; Luboldt, W; Wiedemann, B; Zöphel, K1
Baete, K; Deroose, CM; Haustermans, K; Koole, M; Mortelmans, L; Mottaghy, FM; Terwinghe, C; Van Binnebeek, S; Van Cutsem, E; Vanbilloen, B; Verbruggen, A; Verslype, C1
Breeman, WA; de Blois, E; Konijnenberg, M; Krenning, EP; Kwekkeboom, DJ; Sze Chan, H1
Choyke, PL; Giesel, FL; Haberkorn, U; Haufe, S; Isermann, B; Kauczor, HU; Kratochwil, C; López-Benítez, R; Mier, W1
Brenner, W; Hamm, B; Nogami, M; Pape, UF; Röttgen, R; Schreiter, NF; Steffen, I1
Ballinger, JR; Solanki, KK1
Giesel, FL; Haberkorn, U; Kauczor, HU; Kratochwil, C; Ley, S; Mehndiratta, A; Moltz, JH; Wulfert, S; Zechmann, CM1
Collins, DJ; d'Arcy, JA; Davidson, RL; Koh, DM; Koh, TS; Leach, MO; Lewington, V; Miyazaki, K; Orton, MR; Thng, CH1
Castaldi, P; Giordano, A; Rindi, G; Rufini, V; Treglia, G1
Bolstad, N; Distante, S; Edwin, B; Johnsrud, K; Kazaryan, AM; Nustad, K; Revheim, ME; Warren, DJ1
Antoch, G; Binse, I; Bockisch, A; Boy, C; Brandau, W; Lahner, H; Petersenn, S; Poeppel, TD; Schott, M1
Baum, RP; Kulkarni, HR; Müller, D; Prasad, V; Schuchardt, C; Zachert, C1
Baum, RP; Kulkarni, HR; Schuchardt, C1
Baum, RP; Kulkarni, HR; Prasad, V; Schuchardt, C1
Breeman, WA; Sims-Mourtada, J; Smith, DL1
Briel, M; Brunner, P; Jörg, AC; Koller, MT; Maecke, HR; Marincek, N; Müller-Brand, J; Rochlitz, C; Schindler, C; Walter, MA1
Barone, R; Bouterfa, H; Carlier, P; Chen, T; de Camps, J; Jamar, F; Krenning, EP; Kvols, LK; Labar, D; Mathieu, I; Pauwels, S; Schran, H; Smith, MC; Valkema, R; Walrand, S1
Bartolomei, M; Bodei, L; Chinol, M; Fiorenza, M; Gatti, M; Grana, C; Handkiewicz Junak, D; Lopera Sierra, M; Paganelli, G; Papi, S; Rocca, P1
Bouterfa, H; Bushnell, D; Carlisle, T; Connolly, M; Karwal, M; Menda, Y; Miller, S; O'Dorisio, T; Parker, S; Zehr, P1
Dimitrakopoulou-Strauss, A; Eisenhut, M; Haberkorn, U; Henze, M; Mäcke, HR; Schuhmacher, J; Strauss, LG1
Bartolomei, M; Bodei, L; Chinol, M; Cremonesi, M; Grana, C; Paganelli, G; Rocca, P1
Arnold, R; Bartenstein, P; Bouterfa, H; Buchholz, HG; Förster, GJ; Göke, B; Haus, U; Helisch, A; Pauwels, S; Reber, H; Weber, MM; Wiedenmann, B1
Bernhardt, P; Cremonesi, M; Forrer, F; Maecke, HR; Mueller-Brand, J; Uusijärvi, H; Waldherr, C1
Angelberger, P; Becherer, A; Dudczak, R; Karanikas, G; Kletter, K; Kurtaran, A; Raderer, M; Szabó, M; Wunderbaldinger, P1
Barone, R; Borson-Chazot, F; Chauvin, F; Gogou, L; Jamar, F; Krenning, EP; Kvols, LK; Pauwels, S; Valkema, R; Walrand, S1
Besse, IM; Bushnell, DL; Juweid, ME; Madsen, MT; Menda, Y; O'Dorisio, MS; O'Dorisio, T1
Chen, CH; Hen, SL; Ho, YJ; Hsia, CC; Hung, GU; Lin, WY; Lin, YC; Luo, TY1
de Jong, M; Forrer, F; Krenning, EP; Kwekkeboom, DJ; Valkema, R1
Causer, L; Chittenden, S; Flux, GD; Hindorf, C; Lewington, VJ; Mäcke, HR1
Barone, R; Jamar, F; Konijnenberg, M; Krenning, EP; Kvols, LK; Pauwels, S; Valkema, R; Walrand, S1
Behe, M; Bucher, HC; Goetze, M; Heppeler, A; Jermann, E; Maecke, HR; Mueller-Brand, J; Otte, A; Roser, HW1
Dellas, S; Herrmann, R; Maecke, HR; Mueller-Brand, J; Nitzsche, EU; Otte, A1
Bakker, WH; Kooij, PP; Krenning, EP; Kwekkeboom, DJ; Mäcke, HR1
Herrmann, R; Mäcke, HR; Müller-Brand, J; Otte, A1
Crazzolara, A; Haldemann, A; Maecke, HR; Mueller-Brand, J; Waldherr, C1
Bakker, W; Chen, T; Jamar, F; Krenning, E; Kvols, L; Liu, J; Pauwels, S; Schran, H; Smith, MC; Valkema, R; Yeh, CM1
de Jong, M; Krenning, EP; Kwekkeboom, D1
Haldemann, A; Maecke, HR; Mueller-Brand, J; Pless, M; Waldherr, C1
Grossman, AB; Kaltsas, GA; Mukherjee, JJ1
Cybulla, M; Otte, A; Weiner, SM1
Crazzolara, A; Haldemann, A; Maecke, HR; Mueller-Brand, J; Nitzsche, EU; Pless, M; Schumacher, T; Waldherr, C1
de Jong, M; Krenning, E1

Reviews

10 review(s) available for edotreotide and Neuroendocrine Tumors

ArticleYear
18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
    European journal of nuclear medicine and molecular imaging, 2013, Volume: 40, Issue:6

    Topics: 3-Iodobenzylguanidine; Bronchial Neoplasms; Carcinoma, Merkel Cell; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Lung Neoplasms; Multimodal Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Recurrence; Sensitivity and Specificity; Thyroid Neoplasms; Tomography, Emission-Computed, Single-Photon

2013
Clinical applications of Gallium-68.
    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2013, Volume: 76

    Topics: Bone Neoplasms; Chelating Agents; Citrates; Clinical Trials as Topic; Female; Gallium; Gallium Radioisotopes; Half-Life; Humans; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Tomography, X-Ray Computed

2013
Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
    European review for medical and pharmacological sciences, 2010, Volume: 14, Issue:4

    Topics: Antineoplastic Agents; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Somatostatin; Yttrium Radioisotopes

2010
(68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives.
    Seminars in nuclear medicine, 2011, Volume: 41, Issue:4

    Topics: Forecasting; Gallium Radioisotopes; Humans; Molecular Structure; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Peptides; Positron-Emission Tomography; Radioactivity; Radionuclide Generators; Radiopharmaceuticals; United States

2011
Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.
    Endocrine, 2012, Volume: 42, Issue:1

    Topics: Algorithms; Gallium Radioisotopes; Gastrointestinal Neoplasms; Humans; Multimodal Imaging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Receptors, Somatostatin; Sensitivity and Specificity; Thoracic Neoplasms; Tomography, X-Ray Computed

2012
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.
    European journal of nuclear medicine and molecular imaging, 2004, Volume: 31, Issue:7

    Topics: Animals; Humans; Kidney Diseases; Neuroendocrine Tumors; Octreotide; Radiation Injuries; Radiopharmaceuticals; Radiotherapy; Treatment Outcome; Yttrium Radioisotopes

2004
Neuroendocrine tumors. Peptide receptor radionuclide therapy.
    Best practice & research. Clinical endocrinology & metabolism, 2007, Volume: 21, Issue:1

    Topics: Blood; Heterocyclic Compounds; Humans; Kidney; Liver; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pentetic Acid; Radioisotopes; Receptors, Peptide; Somatostatin; Time Factors

2007
OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy.
    Digestion, 2000, Volume: 62 Suppl 1

    Topics: Animals; Breast Neoplasms; Carcinoma, Small Cell; Dose-Response Relationship, Radiation; Female; Humans; Indium Radioisotopes; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasms; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes

2000
Peptide receptor imaging and therapy.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2000, Volume: 41, Issue:10

    Topics: Humans; Indium Radioisotopes; Neoplasms; Neuroendocrine Tumors; Octreotide; Oligopeptides; Pentetic Acid; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes

2000
The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12 Suppl 2

    Topics: 3-Iodobenzylguanidine; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Octreotide; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Somatostatin; Yttrium Radioisotopes

2001

Trials

15 trial(s) available for edotreotide and Neuroendocrine Tumors

ArticleYear
    The Lancet. Microbe, 2022, Volume: 3, Issue:2

    Topics: Acoustics; Adsorption; Angiotensin II; Animals; Anti-Bacterial Agents; Azithromycin; Calcium; Carbon; Charcoal; Child; Chlorides; Copper; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Resistance, Bacterial; Ecosystem; Epigenesis, Genetic; Female; Fibroblasts; Fibrosis; Gallium Radioisotopes; Heterozygote; Hot Temperature; Humans; Hydrogen-Ion Concentration; Inflammasomes; Inflammation; Kinetics; Macrolides; Magnetic Resonance Imaging; Malawi; Male; Mass Drug Administration; Methylene Blue; Mice; Neuroendocrine Tumors; NLR Family, Pyrin Domain-Containing 3 Protein; Octreotide; Organometallic Compounds; Oxidative Stress; Phenotype; Positron-Emission Tomography; Prevalence; Prognosis; Rats; Receptors, Somatostatin; Retrospective Studies; Rivers; Streptococcus pneumoniae; Trachoma; Water Pollutants, Chemical; Zinc Compounds

2022
Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.
    European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:6

    Topics: Adult; Aged; Digestive System Neoplasms; Female; Humans; Kidney; Kidney Function Tests; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Precision Medicine; Radiation Dosage; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Yttrium Radioisotopes

2014
Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.
    European radiology, 2016, Volume: 26, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Female; Gallium Radioisotopes; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radiopharmaceuticals; Somatostatin; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed

2016
Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases.
    Endocrine-related cancer, 2011, Volume: 18, Issue:5

    Topics: Adult; Aged; Chromogranin A; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Yttrium Radioisotopes

2011
Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI.
    European journal of radiology, 2012, Volume: 81, Issue:10

    Topics: Contrast Media; Female; Gadolinium DTPA; Humans; Indium Radioisotopes; Iopamidol; Magnetic Resonance Imaging; Male; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Tomography, X-Ray Computed

2012
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study.
    Journal of translational medicine, 2013, Jan-15, Volume: 11

    Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Radiation; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiotherapy; Somatostatin; Young Adult; Yttrium Radioisotopes

2013
86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.
    European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:4

    Topics: Adult; Aged; Amino Acids; Arginine; Cohort Studies; Cross-Over Studies; Dizziness; Drug Combinations; Female; Humans; Infusions, Intravenous; Kidney; Lysine; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Radiation Dosage; Radiation Injuries; Radiation-Protective Agents; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed; Vomiting; Yttrium Radioisotopes

2003
Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2003, Volume: 44, Issue:10

    Topics: Adult; Aged; Dose-Response Relationship, Radiation; Female; Humans; Injections, Intravenous; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Quality of Life; Radiography; Radiopharmaceuticals; Radiotherapy Dosage; Treatment Outcome; Yttrium Radioisotopes

2003
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
    European journal of nuclear medicine and molecular imaging, 2004, Volume: 31, Issue:10

    Topics: Body Burden; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Radiation Injuries; Radiation Protection; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Relative Biological Effectiveness; Risk Assessment; Risk Factors; Somatostatin; Tissue Distribution; Yttrium Radioisotopes

2004
A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours.
    European journal of nuclear medicine and molecular imaging, 2004, Volume: 31, Issue:9

    Topics: Aged; Body Burden; Bone Marrow; Humans; Kidney; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Organometallic Compounds; Radiation Dosage; Radiopharmaceuticals; Spleen; Tissue Distribution; Whole-Body Counting

2004
Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2004, Volume: 45, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Dihydroxyphenylalanine; Female; Humans; Indium Radioisotopes; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed

2004
Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005, Volume: 46 Suppl 1

    Topics: Adult; Aged; Algorithms; Body Burden; Dose-Response Relationship, Radiation; Female; Gastrointestinal Neoplasms; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Pancreatic Neoplasms; Radiation Injuries; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Relative Biological Effectiveness; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Treatment Outcome

2005
Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors.
    Cancer biotherapy & radiopharmaceuticals, 2007, Volume: 22, Issue:1

    Topics: Adult; Aged; Dose-Response Relationship, Radiation; Female; Humans; Kidney; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiometry; Yttrium Radioisotopes

2007
Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Nuclear medicine communications, 2008, Volume: 29, Issue:3

    Topics: Adult; Aged; Female; Humans; Indium Radioisotopes; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pentetic Acid; Radiation Dosage; Radiopharmaceuticals; Relative Biological Effectiveness; Somatostatin

2008
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:7

    Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Survival Analysis; Treatment Outcome

2001

Other Studies

62 other study(ies) available for edotreotide and Neuroendocrine Tumors

ArticleYear
    European journal of nuclear medicine and molecular imaging, 2022, Volume: 49, Issue:4

    Topics: COVID-19; COVID-19 Vaccines; Gallium Radioisotopes; Humans; Myocarditis; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Vaccination

2022
Rechallenge With Additional Doses of 177 Lu-DOTATOC After Failure of Maintenance Therapy With Cold Somatostatin Analogs.
    Clinical nuclear medicine, 2022, Aug-01, Volume: 47, Issue:8

    Topics: Female; Humans; Middle Aged; Neuroendocrine Tumors; Octreotide; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin

2022
Serous cystadenoma mimicking cystic pancreatic neuroendocrine tumor on
    Diagnostic and interventional imaging, 2022, Volume: 103, Issue:11

    Topics: Cystadenoma, Serous; Gallium Radioisotopes; Humans; Neuroendocrine Tumors; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals

2022
68 Ga-DOTATOC PET/CT Imaging of a Muscular Solitary Fibrous Tumor.
    Clinical nuclear medicine, 2023, May-01, Volume: 48, Issue:5

    Topics: Aged; Female; Hemangiopericytoma; Humans; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Receptors, Somatostatin; Solitary Fibrous Tumors

2023
Somatostatin receptor activity assessed by
    European journal of nuclear medicine and molecular imaging, 2023, Volume: 50, Issue:9

    Topics: Adaptor Proteins, Signal Transducing; Co-Repressor Proteins; Gallium Radioisotopes; Humans; Molecular Chaperones; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Receptors, Somatostatin; Retrospective Studies; X-linked Nuclear Protein

2023
68 Ga-DOTATOC PET/CT in Pancreatic Metastasis From Clear Cell Renal Cell Carcinoma.
    Clinical nuclear medicine, 2023, Aug-01, Volume: 48, Issue:8

    Topics: Aged; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals

2023
Cervical Ganglioneuroblastoma Diagnosed by
    Journal of nuclear medicine technology, 2023, Dec-05, Volume: 51, Issue:4

    Topics: Child; Female; Gallium Radioisotopes; Ganglioneuroblastoma; Humans; Neuroendocrine Tumors; Octreotide; Opsoclonus-Myoclonus Syndrome; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals

2023
    Endocrine, 2020, Volume: 67, Issue:3

    Topics: Cushing Syndrome; Gallium Radioisotopes; Humans; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed

2020
Particle filter de-noising of voxel-specific time-activity-curves in personalized
    Zeitschrift fur medizinische Physik, 2020, Volume: 30, Issue:2

    Topics: Female; Humans; Lutein; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Prostate-Specific Antigen; Prostatic Neoplasms; Radiometry; Radiopharmaceuticals; Signal-To-Noise Ratio; Single Photon Emission Computed Tomography Computed Tomography; Tomography, Emission-Computed, Single-Photon

2020
Lower
    Clinical endocrinology, 2020, Volume: 92, Issue:3

    Topics: Adult; Aged; Case-Control Studies; Female; Gallium Radioisotopes; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pituitary Gland; Pituitary Neoplasms; Positron-Emission Tomography; Proof of Concept Study; Prospective Studies

2020
Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3: A Somatostatin Receptor Antagonist.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:3

    Topics: Adult; Female; Humans; Liver Neoplasms; Lutetium; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals

2020
Peptide Receptor Radionuclide Therapy Using 225Ac-DOTATOC Achieves Partial Remission in a Patient With Progressive Neuroendocrine Liver Metastases After Repeated β-Emitter Peptide Receptor Radionuclide Therapy.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:3

    Topics: Actinium; Aged; Beta Particles; Disease Progression; Female; Humans; Liver Neoplasms; Neuroendocrine Tumors; Octreotide; Receptors, Peptide; Treatment Outcome

2020
Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent
    Annals of nuclear medicine, 2020, Volume: 34, Issue:4

    Topics: Aged; Antineoplastic Agents; Chromogranin A; Female; Humans; Lutetium; Male; Middle Aged; Monte Carlo Method; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Single Photon Emission Computed Tomography Computed Tomography; Treatment Outcome

2020
Pre- and postoperative
    Clinical endocrinology, 2021, Volume: 94, Issue:6

    Topics: Case-Control Studies; Hormones; Humans; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography

2021
Thyroid metastasis from lung carcinoid detected by
    Endocrine, 2021, Volume: 74, Issue:1

    Topics: Carcinoid Tumor; Gallium Radioisotopes; Humans; Lung; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Thyroid Gland

2021
Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of
    Molecular imaging and biology, 2021, Volume: 23, Issue:5

    Topics: Adult; Female; Gallium Radioisotopes; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals; Somatostatin; Tissue Distribution; Whole Body Imaging

2021
225Ac-DOTATOC-Targeted Somatostatin Receptor α-Therapy in a Patient With Metastatic Neuroendocrine Tumor of the Thymus, Refractory to β-Radiation.
    Clinical nuclear medicine, 2021, Dec-01, Volume: 46, Issue:12

    Topics: Actinium; Humans; Neuroendocrine Tumors; Octreotide; Receptors, Somatostatin; Yttrium Radioisotopes

2021
Dosing
    European journal of nuclear medicine and molecular imaging, 2021, Volume: 49, Issue:1

    Topics: Follow-Up Studies; Humans; Neuroendocrine Tumors; Octreotide; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Renal Insufficiency; Retrospective Studies; Somatostatin; Tomography, X-Ray Computed

2021
Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.
    Surgery, 2018, Volume: 163, Issue:4

    Topics: Aged; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neuroendocrine Tumors; Octreotide; Pancreatectomy; Pancreatic Neoplasms; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome

2018
A five-compartment biokinetic model for
    Medical physics, 2018, Volume: 45, Issue:12

    Topics: Adult; Aged; Female; Humans; Kidney; Male; Middle Aged; Models, Biological; Monte Carlo Method; Neuroendocrine Tumors; Octreotide; Radiotherapy Dosage; Yttrium Radioisotopes

2018
Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI.
    Cancer imaging : the official publication of the International Cancer Imaging Society, 2013, Mar-05, Volume: 13

    Topics: Adult; Female; Gallium Radioisotopes; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging

2013
Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.
    Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:6

    Topics: Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Peptides, Cyclic; Radiopharmaceuticals; Receptors, Somatostatin; Retreatment; Somatostatin; Stomach Neoplasms; Yttrium Radioisotopes

2012
Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.
    European journal of nuclear medicine and molecular imaging, 2013, Volume: 40, Issue:8

    Topics: Aged; Female; Humans; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radiopharmaceuticals; Somatostatin; Stomach Neoplasms; Treatment Outcome; Yttrium Radioisotopes

2013
(68) Ga- DOTA(0) -Tyr(3) octreotide (DOTATOC) positron emission tomography (PET)/CT in five cases of ectopic adrenocorticotropin-secreting tumours.
    Clinical endocrinology, 2014, Volume: 81, Issue:1

    Topics: Adrenocorticotropic Hormone; Adult; Aged; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography

2014
Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: implications for dose optimization.
    Cancer research, 2013, Dec-01, Volume: 73, Issue:23

    Topics: Animals; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cell Proliferation; Chemical Fractionation; Dose-Response Relationship, Drug; Gallium Radioisotopes; Humans; Intestinal Neoplasms; Mice; Mice, Nude; Neuroendocrine Tumors; Octreotide; Prognosis; Radionuclide Imaging; Rats; Receptors, Somatostatin; Solubility; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2013
The role of 68-Ga-DOTATOC CT-PET in surgical tactic for gastric neuroendocrine tumors treatment: our experience: a case report.
    International journal of surgery (London, England), 2014, Volume: 12 Suppl 1

    Topics: Aged; Diagnosis, Differential; Female; Gallium; Gastrectomy; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Stomach Neoplasms; Tomography, X-Ray Computed

2014
²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.
    European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:11

    Topics: Adult; Alpha Particles; Beta Particles; Bismuth; Female; Humans; Male; Molecular Targeted Therapy; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radioisotopes; Receptors, Somatostatin; Retrospective Studies; Tomography, X-Ray Computed; Treatment Failure

2014
Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
    Annals of nuclear medicine, 2015, Volume: 29, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Female; Gallium Radioisotopes; Hormones; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed

2015
Long-term results of PRRT in advanced bronchopulmonary carcinoid.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:3

    Topics: Aged; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cohort Studies; Creatinine; Data Collection; Disease Progression; Disease-Free Survival; Europe; Female; Follow-Up Studies; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Octreotide; Odds Ratio; Organometallic Compounds; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies; Treatment Outcome

2016
Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 58

    Topics: Adult; Disease-Free Survival; Female; Follow-Up Studies; Gallium Radioisotopes; Germany; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Receptors, Somatostatin; Registries; Remission Induction; Time Factors; Treatment Outcome

2016
Clinical efficacy of dual-phase scanning using (68)Ga-DOTATOC-PET/CT in the detection of neuroendocrine tumours.
    Clinical radiology, 2016, Volume: 71, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Female; Gallium Radioisotopes; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results

2016
Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jun-01, Volume: 14, Issue:11

    Topics: Alpha Particles; Animals; Mice; Mice, Nude; Neoplasms, Experimental; Neuroendocrine Tumors; Octreotide; Radioisotopes; Radiopharmaceuticals; Rats; Receptors, Somatostatin; Xenograft Model Antitumor Assays

2008
[Peptide receptor radionuclide therapy of neuroendocrine tumors].
    Ugeskrift for laeger, 2009, Mar-23, Volume: 171, Issue:13

    Topics: Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Receptors, Somatostatin; Yttrium Radioisotopes

2009
Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study.
    Clinical nuclear medicine, 2010, Volume: 35, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Duodenal Neoplasms; Endosonography; Female; Gallium Radioisotopes; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed; Young Adult

2010
Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2010, Volume: 42, Issue:8

    Topics: Female; Humans; Immunohistochemistry; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pentetic Acid; Positron-Emission Tomography; Receptors, Somatostatin; Tomography, X-Ray Computed

2010
Intraoperative identification of a neuroendocrine tumour diagnosed by 68Ga-DOTATOC PET but undetectable by surgical palpation or conventional imaging.
    Nuklearmedizin. Nuclear medicine, 2009, Volume: 48, Issue:5

    Topics: Female; Humans; Middle Aged; Monitoring, Intraoperative; Neuroendocrine Tumors; Octreotide; Palpation; Positron-Emission Tomography; Radiopharmaceuticals

2009
A matter of the heart: myocardial metastases in neuroendocrine tumors.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2010, Volume: 42, Issue:13

    Topics: Adult; Fatal Outcome; Female; Heart Neoplasms; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radiography; Ultrasonography; Whole Body Imaging

2010
The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
    Annals of surgery, 2010, Volume: 252, Issue:5

    Topics: Adult; Aged; Disease Progression; Female; Gallium Radioisotopes; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging

2010
Gastroenteropancreatic neuroendocrine tumors: standardizing therapy monitoring with 68Ga-DOTATOC PET/CT using the example of somatostatin receptor radionuclide therapy.
    Molecular imaging, 2010, Volume: 9, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron-Emission Tomography; Receptors, Somatostatin; Reference Standards; Stomach Neoplasms; Tomography, X-Ray Computed

2010
Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-01, Volume: 29, Issue:19

    Topics: Adult; Disease Progression; Female; Humans; Indium Radioisotopes; Intestinal Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radioisotopes; Receptors, Peptide; Somatostatin; Tomography, X-Ray Computed; Yttrium Radioisotopes

2011
Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours.
    European radiology, 2012, Volume: 22, Issue:2

    Topics: Adult; Aged; Contrast Media; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Observer Variation; Octreotide; Positron-Emission Tomography; Retrospective Studies; Sensitivity and Specificity; Software

2012
What will be required to bring ⁶⁸Ga-labelled peptides into routine clinical use?
    Nuclear medicine communications, 2011, Volume: 32, Issue:12

    Topics: Gallium Radioisotopes; Humans; Multimodal Imaging; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Practice Guidelines as Topic; Radionuclide Generators; Radiopharmaceuticals; Technetium; Tomography, X-Ray Computed; United Kingdom

2011
Neuroendocrine tumor liver metastases: use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response.
    Radiology, 2012, Volume: 263, Issue:1

    Topics: Adult; Aged; Area Under Curve; Contrast Media; Discriminant Analysis; Female; Gadolinium DTPA; Humans; Image Interpretation, Computer-Assisted; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Statistics, Nonparametric; Survival Rate; Tomography, Emission-Computed, Single-Photon; Treatment Outcome

2012
A man with abdominal pain: enough evidence for surgery?
    Clinical chemistry, 2012, Volume: 58, Issue:8

    Topics: Abdominal Pain; Adrenocorticotropic Hormone; Antibodies, Heterophile; Artifacts; Diagnosis, Differential; False Positive Reactions; Gallium Radioisotopes; Humans; Hyperpigmentation; Immunoassay; Male; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pancreatitis; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Water-Electrolyte Imbalance

2012
Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194

    Topics: Aged; Aged, 80 and over; Female; Gallium Radioisotopes; Gastrointestinal Neoplasms; Heterocyclic Compounds, 1-Ring; Humans; Kidney; Male; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed

2013
The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194

    Topics: Adult; Aged; Female; Humans; Kidney; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Receptors, Somatostatin; Whole-Body Counting

2013
Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194

    Topics: Aged; Female; Humans; Kidney; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiometry; Radiopharmaceuticals; Receptors, Somatostatin

2013
Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose?
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194

    Topics: Blood Cells; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiation Dosage; Radiopharmaceuticals; Receptors, Somatostatin; Spleen

2013
SNM 2012 image of the year.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012, Volume: 53, Issue:10

    Topics: Bismuth; Humans; Intestinal Neoplasms; Liver; Neuroendocrine Tumors; Nuclear Medicine; Octreotide; Pancreatic Neoplasms; Radioisotopes; Radionuclide Imaging; Societies, Scientific; Stomach Neoplasms; Treatment Failure

2012
The untapped potential of Gallium 68-PET: the next wave of ⁶⁸Ga-agents.
    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2013, Volume: 76

    Topics: Amine Oxidase (Copper-Containing); Cell Adhesion Molecules; Gallium Radioisotopes; Glucagon-Like Peptide 1; Half-Life; Insulinoma; Neuroendocrine Tumors; Octreotide; Oligopeptides; Organometallic Compounds; Positron-Emission Tomography; Radionuclide Generators; Radiopharmaceuticals; Receptors, Bombesin; Receptors, Somatostatin; Single-Domain Antibodies; Somatostatin; Vascular Endothelial Growth Factor A

2013
90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies.
    Biopolymers, 2002, Volume: 66, Issue:6

    Topics: Humans; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Somatostatin

2002
Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET.
    European journal of nuclear medicine and molecular imaging, 2004, Volume: 31, Issue:3

    Topics: Gallium Radioisotopes; Humans; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin

2004
Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006, Volume: 47, Issue:4

    Topics: 3-Iodobenzylguanidine; Drug Therapy, Combination; Humans; Iodine Radioisotopes; Models, Biological; Neuroendocrine Tumors; Octreotide; Radiation Dosage; Radiopharmaceuticals; Yttrium Radioisotopes

2006
A comparison of biodistribution between 111In-DTPA octreotide and 111In-DOTATOC in rats bearing pancreatic tumors.
    The Journal of veterinary medical science, 2006, Volume: 68, Issue:4

    Topics: Animals; Indium Radioisotopes; Male; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pentetic Acid; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Tissue Distribution

2006
DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.
    European journal of nuclear medicine, 1997, Volume: 24, Issue:7

    Topics: Abdominal Neoplasms; Adult; Humans; Indium Radioisotopes; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pentetic Acid; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Sensitivity and Specificity; Yttrium Radioisotopes

1997
Yttrium-90-labelled somatostatin-analogue for cancer treatment.
    Lancet (London, England), 1998, Feb-07, Volume: 351, Issue:9100

    Topics: Adult; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes

1998
Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1999, Volume: 40, Issue:5

    Topics: Adult; Aged; Female; Humans; Indium Radioisotopes; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiation Dosage; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Tissue Distribution; Yttrium Radioisotopes

1999
[Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].
    Praxis, 1999, Aug-15, Volume: 88, Issue:31-32

    Topics: Female; Follow-Up Studies; Humans; Middle Aged; Neuroendocrine Tumors; Octreotide; Pilot Projects; Prospective Studies; Radiation Injuries; Radionuclide Imaging; Radiotherapy Dosage; Receptors, Somatostatin; Treatment Outcome; Yttrium Radioisotopes

1999
Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2000, Volume: 12, Issue:2

    Topics: Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Paraplegia; Radiopharmaceuticals; Somatostatin; Spinal Cord Compression; Spinal Neoplasms; Thoracic Vertebrae; Yttrium Radioisotopes

2000
Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe?
    Medical science monitor : international medical journal of experimental and clinical research, 2002, Volume: 8, Issue:4

    Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma, Medullary; Humans; Hypertension, Renal; Kidney Failure, Chronic; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Thyroid Neoplasms; Yttrium Radioisotopes

2002
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2002, Volume: 43, Issue:5

    Topics: Carcinoid Tumor; Humans; Middle Aged; Neuroendocrine Tumors; Octreotide; Pain, Intractable; Radionuclide Imaging; Radiopharmaceuticals; Yttrium Radioisotopes

2002
New advances in peptide receptor radionuclide therapy.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2002, Volume: 43, Issue:5

    Topics: Humans; Kidney; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Yttrium Radioisotopes

2002